Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ayala Pharmaceuticals, Inc.ADXS · Entity 93434 | Chief Scientific Officer | November 05, 2018 | November 07, 2018 |
| OS Therapies IncOSTX · Entity 6950 | See Remarks | January 22, 2026 | February 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ayala Pharmaceuticals, Inc.
Report date November 05, 2018 · Filed November 07, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 231,206 |
Reported balance
After 2018-11-05 transaction · row 1
1 source rowRow 1 · 2018-11-05 · Sale · Disposed 3,963 · Balance 231,206 F1: In connection with the vesting of 9,534 shares on November 5, 2018, a total of 3,963 of such shares were withheld by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F2: Reflects the weighted average sale price. The range of prices for such transaction is $0.57 to $0.58. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price in accordance with the issuer's corporate policies. |
| OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.54 · Expires 2028-11-05 | Direct | 150,000 |
Reported balance
After 2018-11-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-11-05 · Grant · Acquired 150,000 · Balance 150,000 F3: This award relates to the annual long term incentive grant awarded by the Compensation Committee following the completion of our 2018 Fiscal Year and is subject to the terms of our 2015 Incentive Plan. The award vests one-third on November 5, 2019, one-third on November 5, 2020, and will be fully vested on November 5, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the vesting of 9,534 shares on November 5, 2018, a total of 3,963 of such shares were withheld by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies.
F2: Reflects the weighted average sale price. The range of prices for such transaction is $0.57 to $0.58. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price in accordance with the issuer's corporate policies.
F3: This award relates to the annual long term incentive grant awarded by the Compensation Committee following the completion of our 2018 Fiscal Year and is subject to the terms of our 2015 Incentive Plan. The award vests one-third on November 5, 2019, one-third on November 5, 2020, and will be fully vested on November 5, 2021.
OS Therapies Inc
Report date January 22, 2026 · Filed February 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.34 · Expires 2036-01-22 | Direct | 100,000 |
Reported balance
After 2026-01-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-22 · Grant · Acquired 100,000 · Balance 100,000 F1: On January 22, 2026, the reporting person was granted options to purchase 100,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement. These options vest in full on the one-year anniversary of the date of grant, provided that the reporting person is serving as an employee of the issuer on such date. |
| Common StockSEC Table I · non-derivative | Direct | 200,000 |
Reported balance
Holding disclosure · report date 2026-01-22 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 200,000 |
Filing footnotes · ownership attribution and instrument terms
F1: On January 22, 2026, the reporting person was granted options to purchase 100,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement. These options vest in full on the one-year anniversary of the date of grant, provided that the reporting person is serving as an employee of the issuer on such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 22, 2026 Filed Feb 13, 2026 16:41 UTC | OS Therapies Inc OSTX · Entity 6950 | GrantStock options (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001213900-26-016499 · ownership.xml · derivative · entry 2 PETIT ROBERT · CIK 0001576077 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2036-01-22 F1 · derivative.exercise_date: On January 22, 2026, the reporting person was granted options to purchase 100,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement. These options vest in full on the one-year anniversary of the date of grant, provided that the reporting person is serving as an employee of the issuer on such date. Read SEC document |
| October 21, 2025 Filed Dec 19, 2025 18:31 UTC | OS Therapies Inc OSTX · Entity 6950 | GrantStock options (right to buy) · Derivative | 500,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001213900-25-123999 · ownership.xml · derivative · entry 2 PETIT ROBERT · CIK 0001576077 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2035-10-21 F1 · derivative.exercise_date: On October 21, 2025, the reporting person was granted options to purchase 500,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement. These options vest in full on the one-year anniversary of the date of grant, provided that the reporting person is serving as an employee of the issuer on such date. Read SEC document |
| November 05, 2018 Filed Nov 7, 2018 17:00 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantOption · Derivative | 150,000 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001493152-18-015360 · ownership.xml · derivative · entry 2 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-11-05 F3 · shares: This award relates to the annual long term incentive grant awarded by the Compensation Committee following the completion of our 2018 Fiscal Year and is subject to the terms of our 2015 Incentive Plan. The award vests one-third on November 5, 2019, one-third on November 5, 2020, and will be fully vested on November 5, 2021. Read SEC document |
| November 05, 2018 Filed Nov 7, 2018 17:00 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | SaleCommon Stock | 3,963 | $0.58 | $2,298.54 |
DisclosureSEC source: 0001493152-18-015360 · ownership.xml · nonDerivative · entry 1 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,206 F1 · shares: In connection with the vesting of 9,534 shares on November 5, 2018, a total of 3,963 of such shares were withheld by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F2 · price: Reflects the weighted average sale price. The range of prices for such transaction is $0.57 to $0.58. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price in accordance with the issuer's corporate policies. Read SEC document |
| November 02, 2018 Filed Nov 5, 2018 18:00 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | SaleCommon Stock | 8,491 | $0.56 | $4,754.96 |
DisclosureSEC source: 0001493152-18-015218 · ownership.xml · nonDerivative · entry 1 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,169 F1 · shares: In connection with the vesting of 28,826 shares on April 2, 2018, a total of 8,491 of such shares were withheld by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. Read SEC document |
| July 31, 2018 Filed Aug 1, 2018 16:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 1,505 | $1.46 | $2,197.30 |
DisclosureSEC source: 0001493152-18-010799 · ownership.xml · nonDerivative · entry 1 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,660 F1 · shares: The reporting person voluntarily purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount of 1,791 shares of which 286 shares were forfeited to pay withholding taxes associated with the stock issuance. Read SEC document |
| June 29, 2018 Filed Jul 2, 2018 16:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 1,516 | $1.45 | $2,198.20 |
DisclosureSEC source: 0001493152-18-009554 · ownership.xml · nonDerivative · entry 3 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,155 F2 · shares: The reporting person voluntarily purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount of 1,804 shares of which 288 shares were forfeited to pay withholding taxes associated with the stock issuance. Read SEC document |
| June 18, 2018 Filed Jul 2, 2018 16:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 9,000 | $1.72 | $15,480.00 |
DisclosureSEC source: 0001493152-18-009554 · ownership.xml · nonDerivative · entry 2 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,639 F1 · shares: Represents a voluntary at market stock purchase by the reporting person on the open market Read SEC document |
| June 12, 2018 Filed Jul 2, 2018 16:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 5,000 | $1.84 | $9,200.00 |
DisclosureSEC source: 0001493152-18-009554 · ownership.xml · nonDerivative · entry 1 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,639 F1 · shares: Represents a voluntary at market stock purchase by the reporting person on the open market Read SEC document |
| May 31, 2018 Filed Jun 1, 2018 16:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 1,765 | $1.82 | $3,212.30 |
DisclosureSEC source: 0001493152-18-008133 · form4.xml · nonDerivative · entry 1 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,639 F1 · shares: The reporting person voluntarily purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount of 2,156 shares of which 391 shares were forfeited to pay withholding taxes associated with the stock issuance. Read SEC document |
| April 30, 2018 Filed May 2, 2018 16:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 1,374 | $1.60 | $2,198.40 |
DisclosureSEC source: 0001493152-18-006133 · form4.xml · nonDerivative · entry 1 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,874 F1 · shares: The reporting person voluntarily purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount of 1,635 shares of which 261 shares were forfeited to pay withholding taxes associated with the stock issuance. Read SEC document |
| April 02, 2018 Filed Apr 3, 2018 16:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | SaleCommon Stock | 2,193 | $1.62 | $3,552.66 |
DisclosureSEC source: 0001493152-18-004693 · form4.xml · nonDerivative · entry 2 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,500 F2 · shares: In connection with the vesting of 7,773 shares on April 2, 2018, a total of 2,193 of such shares were withheld by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F3 · price: Reflects the weighted average sale price. The range of prices for such transaction is $1.61 to $1.63. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price in accordance with the issuer's corporate policies. Read SEC document |
| March 29, 2018 Filed Apr 3, 2018 16:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 1,111 | $1.69 | $1,877.59 |
DisclosureSEC source: 0001493152-18-004693 · form4.xml · nonDerivative · entry 1 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,693 F1 · shares: The reporting person voluntarily purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount 1,548 shares of which 437 shares were forfeited to pay withholding taxes associated with the stock issuance. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 16:31 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 1,182 | $1.86 | $2,198.52 |
DisclosureSEC source: 0001493152-18-002792 · form4.xml · nonDerivative · entry 1 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,582 F1 · shares: The reporting person voluntarily purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount 1,406 shares of which 224 shares were forfeited to pay withholding taxes associated with the stock issuance. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 16:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 696 | $2.96 | $2,060.16 |
DisclosureSEC source: 0001493152-18-001417 · form4.xml · nonDerivative · entry 1 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,400 F1 · shares: The reporting person voluntarily purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount 884 shares of which 188 shares were forfeited to pay withholding taxes associated with the stock issuance. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 18:00 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 752 | $2.84 | $2,135.68 |
DisclosureSEC source: 0001493152-18-000116 · form4.xml · nonDerivative · entry 1 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,704 F1 · shares: The reporting person voluntarily purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount 921 shares of which 169 shares were forfeited to pay withholding taxes associated with the stock issuance. Read SEC document |
| November 30, 2017 Filed Dec 4, 2017 16:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 1,035 | $2.99 | $3,094.65 |
DisclosureSEC source: 0001493152-17-014143 · form4.xml · nonDerivative · entry 1 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,952 F1 · shares: The reporting person voluntarily purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount of 1,312 shares of which 277 shares were forfeited to pay withholding taxes associated with the stock issuance. Read SEC document |
| November 06, 2017 Filed Nov 6, 2017 18:00 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | SaleCommon Stock | 3,723 | $3.30 | $12,285.90 |
DisclosureSEC source: 0001493152-17-012504 · form4.xml · nonDerivative · entry 1 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,917 F1 · shares: In connection with the vesting of 9,533 shares on November 3, 2017, a total of 3,723 of such shares were withheld by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F2 · price: Reflects the weighted average sale price. The range of prices for such transaction is $3.30 to $3.31. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 02, 2017 Filed Nov 2, 2017 17:54 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | SaleCommon Stock | 12,625 | $3.19 | $40,273.75 |
DisclosureSEC source: 0001493152-17-012358 · form4.xml · nonDerivative · entry 2 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,640 F2 · shares: In connection with the vesting of 28,827 shares on November 1, 2017, a total of 12,625 of such shares were withheld by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F3 · price: Reflects the weighted average sale price. The range of prices for such transaction is $3.15 to $3.21. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 18:00 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantOption · Derivative | 100,000 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0001493152-17-012504 · form4.xml · derivative · entry 2 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common stock · 100,000 shares Expires 2027-11-02 F3 · shares: This award relates to the annual long term incentive grant awarded by the Compensation Committee following the completion of our 2017 Fiscal Year and is subject to the terms of our 2015 Incentive Plan. The award vests one-third on November 2, 2018, one-third on November 2, 2019, and will be fully vested on November 2, 2020. Read SEC document |
| October 31, 2017 Filed Nov 2, 2017 17:54 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 432 | $3.40 | $1,468.80 |
DisclosureSEC source: 0001493152-17-012358 · form4.xml · nonDerivative · entry 1 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,265 F1 · shares: The reporting person voluntarily purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount of 769 shares of which 337 shares were forfeited to pay withholding taxes associated with the stock issuance. Read SEC document |
| September 29, 2017 Filed Oct 2, 2017 16:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 511 | $4.18 | $2,135.98 |
DisclosureSEC source: 0001493152-17-011142 · form4.xml · nonDerivative · entry 1 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,833 F1 · shares: The reporting person voluntarily purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount of 626 shares of which 115 shares were forfeited to pay withholding taxes associated with the stock issuance. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 16:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 318 | $6.81 | $2,165.58 |
DisclosureSEC source: 0001493152-17-010228 · form4.xml · nonDerivative · entry 1 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,322 F1 · shares: The reporting person voluntarily purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount of 384 shares of which 66 shares were forfeited to pay withholding taxes associated with the stock issuance. Read SEC document |
| July 31, 2017 Filed Aug 1, 2017 16:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 335 | $6.47 | $2,167.45 |
DisclosureSEC source: 0001493152-17-008350 · form4.xml · nonDerivative · entry 1 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,004 F1 · shares: The reporting person voluntarily purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount of 405 shares of which 70 shares were forfeited to pay withholding taxes associated with the stock issuance. Read SEC document |
| June 30, 2017 Filed Jul 3, 2017 16:31 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 477 | $6.49 | $3,095.73 |
DisclosureSEC source: 0001493152-17-007455 · form4.xml · nonDerivative · entry 1 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,669 F1 · shares: The reporting person voluntarily purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount of 604 shares of which 127 shares were forfeited to pay withholding taxes associated with the stock issuance. Read SEC document |
| June 19, 2017 Filed Jun 20, 2017 18:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 57,199 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-17-006930 · form4.xml · nonDerivative · entry 1 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,192 F1 · shares: As part of his long-term incentive compensation, the reporting person was previously granted a performance based restricted stock award by the Compensation Committee. The specific terms of performance, which were required to be achieved prior to earning the award, have now been met. These performance terms were (i) the FDA acceptance of the ADXS-NEO IND, and (ii) the opening of a certain pre-defined number of clinical sites for the AIM2CERV study prior to November 1, 2017. The award vests one-third in November 2017, one-third in November 2018, and will be fully vested in November 2019. Read SEC document |
| May 31, 2017 Filed Jun 1, 2017 16:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 265 | $8.07 | $2,138.55 |
DisclosureSEC source: 0001493152-17-006086 · form4.xml · nonDerivative · entry 1 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,993 F1 · shares: The reporting voluntarily person purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount of 324 shares of which 59 shares were forfeited to pay withholding taxes associated with the stock issuance. Read SEC document |
| May 01, 2017 Filed May 1, 2017 17:31 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 57,881 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-17-004629 · form4.xml · nonDerivative · entry 2 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,728 F2 · shares: The award vests one-third on November 1, 2017, one-third on November 1, 2018, and will be fully vested on November 1, 2019. Read SEC document |
| April 28, 2017 Filed May 1, 2017 17:31 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 250 | $8.56 | $2,140.00 |
DisclosureSEC source: 0001493152-17-004629 · form4.xml · nonDerivative · entry 1 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,847 F1 · shares: The reporting voluntarily person purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount of 306 shares of which 56 shares were forfeited to pay withholding taxes associated with the stock issuance. Read SEC document |
| March 31, 2017 Filed Apr 3, 2017 16:38 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | SaleCommon Stock | 2,454 | $8.24 | $20,220.96 |
DisclosureSEC source: 0001493152-17-003407 · form4.xml · nonDerivative · entry 2 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,597 F2 · shares: In connection with the vesting of 7,773 shares on March 30, 2017, a total of 2,454 of such shares were withheld by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F3 · price: Reflects the weighted average sale price. The range of prices for such transaction is $8.23 to $8.26. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 31, 2017 Filed Apr 3, 2017 16:38 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 219 | $8.17 | $1,789.23 |
DisclosureSEC source: 0001493152-17-003407 · form4.xml · nonDerivative · entry 1 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,051 F1 · shares: The reporting voluntarily person purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). The Company utilizes the net withholding method for each monthly purchase. The reporting person purchased a gross amount of 320 shares of which 101 shares were forfeited to pay withholding taxes associated with the stock issuance. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 16:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | Tax withholdingCommon Stock | 52 | $8.79 | $457.08 |
DisclosureSEC source: 0001493152-17-002030 · form4.xml · nonDerivative · entry 2 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,832 F2 · shares: Represents shares forfeited by the reporting person in order to pay withholding taxes associated with the stock issuance. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 16:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 298 | $8.79 | $2,619.42 |
DisclosureSEC source: 0001493152-17-002030 · form4.xml · nonDerivative · entry 1 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,884 F1 · shares: The reporting person purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 16:31 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | Tax withholdingCommon Stock | 48 | $8.96 | $430.08 |
DisclosureSEC source: 0001493152-17-001038 · form4.xml · nonDerivative · entry 2 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,586 F2 · shares: Represents shares forfeited by the reporting person in order to pay withholding taxes associated with the stock issuance. Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 16:31 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 282 | $8.96 | $2,526.72 |
DisclosureSEC source: 0001493152-17-001038 · form4.xml · nonDerivative · entry 1 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,634 F1 · shares: The reporting person purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). Read SEC document |
| December 30, 2016 Filed Jan 3, 2017 17:28 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | Tax withholdingCommon Stock | 93 | $7.16 | $665.88 |
DisclosureSEC source: 0001493152-17-000065 · form4.xml · nonDerivative · entry 2 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,352 F2 · shares: Represents shares forfeited by the reporting person in order to pay withholding taxes associated with the stock issuance. Read SEC document |
| December 30, 2016 Filed Jan 3, 2017 17:28 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 476 | $7.16 | $3,408.16 |
DisclosureSEC source: 0001493152-17-000065 · form4.xml · nonDerivative · entry 1 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,445 F1 · shares: The reporting person purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). Read SEC document |
| November 30, 2016 Filed Dec 1, 2016 16:34 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | Tax withholdingCommon Stock | 49 | $8.31 | $407.19 |
DisclosureSEC source: 0001493152-16-015591 · form4.xml · nonDerivative · entry 2 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,969 F2 · shares: Represents shares forfeited by the reporting person in order to pay withholding taxes associated with the stock issuance. Read SEC document |
| November 30, 2016 Filed Dec 1, 2016 16:34 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 274 | $8.31 | $2,276.94 |
DisclosureSEC source: 0001493152-16-015591 · form4.xml · nonDerivative · entry 1 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,018 F1 · shares: The reporting person purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). Read SEC document |
| November 03, 2016 Filed Nov 7, 2016 16:30 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantOption · Derivative | 68,906 | $0.00 Strike: $7.71 | $0.00 |
DisclosureSEC source: 0001493152-16-014573 · form4.xml · derivative · entry 1 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,906 Underlying: Common Stock · 68,906 shares Expires 2026-11-03 F1 · shares: This award relates to the annual long term incentive grant awarded by the Compensation Committee following the completion of our 2016 Fiscal Year and is subject to the terms of our 2015 Incentive Plan. The award vests one-third on November 3, 2017, one-third on November 3, 2018, and will be fully vested on November 3, 2019. Read SEC document |
| November 02, 2016 Filed Nov 2, 2016 16:41 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | SaleCommon Stock | 2,797 | $8.32 | $23,271.04 |
DisclosureSEC source: 0001493152-16-014445 · form4.xml · nonDerivative · entry 3 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,744 F3 · shares: In connection with the vesting of 6,667 shares on October 31, 2016, a total of 2,797 of such shares were withheld by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F4 · price: Reflects the weighted average sale price. The range of prices for such transaction is $8.19 to $8.46. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 31, 2016 Filed Nov 2, 2016 16:41 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | Tax withholdingCommon Stock | 118 | $8.09 | $954.62 |
DisclosureSEC source: 0001493152-16-014445 · form4.xml · nonDerivative · entry 2 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,541 F2 · shares: Represents shares forfeited by the reporting person in order to pay withholding taxes associated with the stock issuance. Read SEC document |
| October 31, 2016 Filed Nov 2, 2016 16:41 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 281 | $8.09 | $2,273.29 |
DisclosureSEC source: 0001493152-16-014445 · form4.xml · nonDerivative · entry 1 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,659 F1 · shares: The reporting person purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 18:24 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | Tax withholdingCommon Stock | 32 | $10.69 | $342.08 |
DisclosureSEC source: 0001493152-16-013844 · form4.xml · nonDerivative · entry 2 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,378 F2 · shares: Represents shares forfeited by the reporting person in order to pay withholding taxes associated with the stock issuance. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 18:24 UTC | Ayala Pharmaceuticals, Inc. ADXS · Entity 93434 | GrantCommon Stock | 213 | $10.69 | $2,276.97 |
DisclosureSEC source: 0001493152-16-013844 · form4.xml · nonDerivative · entry 1 PETIT ROBERT · CIK 0001576077 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,410 F1 · shares: The reporting person purchases restricted stock directly from the Company at market price on the last trading day of the month pursuant to an arrangement that was approved by the Compensation Committee of the Company's Board of Directors in a manner that satisfied Exchange Act Rule 16b-3(d). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.